Senkyunolide A is a phthalide associated with celery seed and Ligusticum/Chuanxiong chemistry, and it has a more developed isolated-compound literature than many aroma constituents. The strongest live evidence supports identity, plant-occurrence and quality-marker status, plus preclinical pharmacology around vasorelaxation and pharmacokinetic behavior showing low oral bioavailability and extensive metabolism. One older neural-cell paper on senkyunolide A was later retracted, so AromaForge should avoid relying on that result and instead emphasize the better-supported chemistry, pharmacokinetic, and ex vivo data with explicit caution about translational limits.
Chemical identity and composition
NIST and archive oil records align senkyunolide A with CAS 62006-39-7 and the non-stereospecific InChIKey form ZPIKVDODKLJKIN-UHFFFAOYSA-N, while PubChem's stereospecific (3S) entry surfaces CAS 63038-10-8 and the stereochemistry-bearing InChIKey ZPIKVDODKLJKIN-NSHDSACASA-N. For archive consistency, the main CAS here follows the celery-seed/NIST convention already used in oil data, with the registry split noted explicitly. In the archive's celery seed record, senkyunolide A is a recurring phthalide marker at roughly 2.2-3.8%.
Aroma and practical use
- Use the recorded celery-like, herbaceous, warm, characteristic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2007 rat pharmacokinetic study found senkyunolide A was rapidly absorbed after oral dosing but had low oral bioavailability of about 8%, with instability in the gastrointestinal tract and hepatic first-pass metabolism accounting for most of the loss.
A 2007 rat pharmacokinetic study found senkyunolide A was rapidly absorbed after oral dosing but had low oral bioavailability of about 8%, with instability in the gastrointestinal tract and hepatic first-pass metabolism accounting for most of the loss.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2007 ex vivo study reported that senkyunolide A relaxed rat isolated-aorta contractions triggered by prostaglandin analog, phenylephrine, 5-hydroxytryptamine, and KCl, with effects not blocked by endothelium removal or several pathway inhibitors tested.
A 2007 ex vivo study reported that senkyunolide A relaxed rat isolated-aorta contractions triggered by prostaglandin analog, phenylephrine, 5-hydroxytryptamine, and KCl, with effects not blocked by endothelium removal or several pathway inhibitors tested.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2020 hepatocyte metabolism study found senkyunolide A was metabolically unstable and produced 14 metabolites, with hydroxylation, epoxidation, aromatization, and glutathione conjugation identified as the main metabolic pathways.
A 2020 hepatocyte metabolism study found senkyunolide A was metabolically unstable and produced 14 metabolites, with hydroxylation, epoxidation, aromatization, and glutathione conjugation identified as the main metabolic pathways.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2005 analytical study concluded that senkyunolide A was a useful standard compound for quality evaluation and chemical differentiation between Rhizoma chuanxiong and Angelica sinensis.
A 2005 analytical study concluded that senkyunolide A was a useful standard compound for quality evaluation and chemical differentiation between Rhizoma chuanxiong and Angelica sinensis.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The most directly retrieved constituent-specific literature for senkyunolide A is pharmacokinetic and preclinical rather than formal human safety testing.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Registry identity varies between sources, with both 62006-39-7 and 63038-10-8 encountered for senkyunolide A-related entries; archive users should verify which stereochemical record a supplier or paper is using.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
A 2018 neural-cell paper on senkyunolide A was retracted in 2022, so it should not be used as a safety or efficacy anchor.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
vasorelaxation independent of endothelium, guanylate cyclase, adenylate cyclase, and non-selective potassium-channel blockade in rat aorta
A 2007 rat isolated-aorta study found senkyunolide A relaxed contractions induced by multiple contractile agents, and the effect was not abolished by endothelium removal or several pathway inhibitors used in the experiment.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
rapid metabolism through hydroxylation, epoxidation, aromatization, and glutathione-conjugation pathways
A 2020 hepatocyte profiling study identified 14 metabolites and described hydroxylation, epoxidation, aromatization, and GSH conjugation as major metabolic routes across species.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- A major senkyunolide A neural-cell paper was retracted, which narrows the reliable isolated-compound evidence base.
- No constituent-specific human clinical safety study was verified in this pass.
- CAS and stereochemical registry differences across NIST, PubChem, and supplier records require careful reconciliation when matching analytical standards or literature.
- No IFRA, RIFM, Tisserand & Young, or EU Annex III dermal limit or sensitization determination was found for senkyunolide A as of 2026-07-13 verification pass; the previous dermal_limit_pct value of 0.8 and sensitizing:true had no locatable citation and were corrected to null/false.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.